Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Johnson and Johnson
Colorcon
Express Scripts

Last Updated: May 26, 2022

Investigational Drug Information for Sirukumab


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Sirukumab?

Sirukumab is an investigational drug.

There have been 13 clinical trials for Sirukumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 15th 2012.

The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Polymyalgia Rheumatica. The leading clinical trial sponsors are GlaxoSmithKline, Janssen Research & Development, LLC, and Centocor, Inc.

There are six US patents protecting this investigational drug and fifty-five international patents.

Recent Clinical Trials for Sirukumab
TitleSponsorPhase
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19Janssen Pharmaceutica N.V., BelgiumPhase 2
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia RheumaticaGlaxoSmithKlinePhase 3
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled AsthmaGlaxoSmithKlinePhase 2

See all Sirukumab clinical trials

Clinical Trial Summary for Sirukumab

Top disease conditions for Sirukumab
Top clinical trial sponsors for Sirukumab

See all Sirukumab clinical trials

US Patents for Sirukumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sirukumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
Sirukumab See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
Sirukumab See Plans and Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) See Plans and Pricing
Sirukumab See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
Sirukumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
Sirukumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sirukumab

Drugname Country Document Number Estimated Expiration Related US Patent
Sirukumab Australia AU2013220749 2032-02-15 See Plans and Pricing
Sirukumab Brazil BR112014019627 2032-02-15 See Plans and Pricing
Sirukumab Canada CA2862476 2032-02-15 See Plans and Pricing
Sirukumab China CN104114705 2032-02-15 See Plans and Pricing
Sirukumab China CN108570468 2032-02-15 See Plans and Pricing
Sirukumab Denmark DK2814963 2032-02-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Johnson and Johnson
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.